Skip to main content

Ingenuity Signs $6M CRADA with FDA to Develop Biomarker, PGx Informatics

NEW YORK (GenomeWeb News) - Ingenuity Systems has entered into a three-year, $6 million Cooperative Research and Development Agreement with the US Food and Drug Administration that will expand the company’s content and software used in biomarker, Pharmacogenomic, and toxicogenomic research, the company said today.
Ingenuity said the partnership is aimed at supporting the FDA’s drug toxicity and side-effects research programs.
Ingenuity, a member of the Biomarkers Consortium, markets IPABiomarker, a module of its Ingenuity Pathways Analysis software that is designed to help researchers explore, analyze and interpret biomarker-related scientific literature and data.
The FDA has already integrated IPA with its in-house ArrayTrack bioinformatics system under an agreement penned in 2005.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.